$181 Million is the total value of VHCP Management, LLC's 18 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NBIX | Sell | Neurocrine Biosciences Inc | $14,391,000 | -45.3% | 1,271,303 | -35.3% | 7.95% | -59.3% |
| HPTX | Sell | Hyperion Therapeutics Inc | $5,685,000 | +1.3% | 217,571 | -14.7% | 3.14% | -24.6% |
| VNDA | Sell | Vanda Pharmaceuticals Inc | $5,377,000 | -15.5% | 491,075 | -37.6% | 2.97% | -37.1% |
| BIOD | Sell | Biodel Inc | $4,037,000 | -33.2% | 1,281,592 | -11.4% | 2.23% | -50.4% |
| ANTH | Exit | Anthera Pharmaceuticals Inc | $0 | – | -1,437,623 | -100.0% | -0.50% | – |
| STML | Exit | Stemline Therapeutics Inc | $0 | – | -50,000 | -100.0% | -0.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DBV Technologies | 14 | Q4 2016 | 33.5% |
| BioCryst Pharmaceuticals Inc | 13 | Q4 2016 | 11.9% |
| Ocera Therapeutics | 13 | Q4 2016 | 4.9% |
| Anacor Pharmaceuticals Inc | 12 | Q1 2016 | 35.6% |
| Heron Therapeutics Inc | 12 | Q4 2016 | 20.5% |
| Flamel Technologies S.A. | 12 | Q4 2016 | 6.1% |
| GW Pharmaceuticals | 11 | Q4 2015 | 19.9% |
| Lipocine Inc | 11 | Q4 2016 | 7.5% |
| Stemline Therapeutics Inc | 11 | Q4 2016 | 1.7% |
| Zafgen Inc | 10 | Q3 2016 | 5.7% |
View VHCP Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2018-02-28 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-14 |
| 13F-HR | 2016-08-12 |
| 13F-HR | 2016-05-13 |
| 13F-HR | 2016-02-12 |
| 13F-HR | 2015-11-13 |
| 13F-HR | 2015-08-13 |
| 3 | 2015-06-17 |
| 13F-HR | 2015-05-14 |
View VHCP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.